10 studies found for:    SAR236553 | Sanofi [Lead] | Regeneron | Phase 3
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: matching placebo alirocumab SAR236553 (REGN727);   Drug: Ezetimibe;   Other: matching placebo for Ezetimibe
2 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
3 Active, not recruiting Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo (for alirocumab);   Drug: Ezetimibe;   Drug: Placebo (for ezetimibe);   Drug: Statin therapy
4 Completed Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)
Condition: Hypercholesterolaemia
Interventions: Drug: Alirocumab;   Drug: Placebo;   Drug: Lipid-Modifying Therapy (LMT)
5 Completed Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition: Hypercholesterolemia
Interventions: Drug: Placebo;   Drug: Alirocumab
6 Completed Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo
7 Completed Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo;   Drug: Lipid-Modifying Therapy (LMT)
8 Recruiting Open Label Study of Long Term Safety Evaluation of Alirocumab
Condition: Hypercholesterolemia
Intervention: Drug: Alirocumab SAR236553 (REGN727)
9 Active, not recruiting Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo (for alirocumab)
10 Active, not recruiting Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: Placebo (for alirocumab);   Drug: Alirocumab;   Drug: Statin therapy

Indicates status has not been verified in more than two years